Markets:

Overview

News

Currencies

International

Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

8.980 -0.260 (-2.81%)

Streaming Delayed Price Updated: 10:24 AM EDT, Jun 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday ↗

November 22, 2024

Via Benzinga

Dow Jumps 300 Points; Gap Posts Upbeat Earnings ↗

November 22, 2024

Via Benzinga

Topics Stocks

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

November 21, 2024

From Replimune Group Inc

Via GlobeNewswire

Replimune Group: Q3 Earnings Insights ↗

February 08, 2024

Via Benzinga

Barclays Maintains Overweight Rating for Replimune Group: Here's What You Need To Know ↗

December 06, 2023

Via Benzinga

The Latest Analyst Ratings for Replimune Group ↗

August 01, 2023

Via Benzinga

Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

November 12, 2024

From Replimune Group Inc

Via GlobeNewswire

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

November 09, 2024

From Replimune Group Inc

Via GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 08, 2024

From Replimune Group Inc

Via GlobeNewswire

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

October 30, 2024

From Replimune Group Inc

Via GlobeNewswire

REPL Stock Earnings: Replimune Group Beats EPS for Q1 2025 ↗

August 08, 2024

REPL stock results show that Replimune Group beat analyst estimates for earnings per share the first quarter of 2025.

Via InvestorPlace

Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

June 07, 2024

Via Benzinga

S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat ↗

June 06, 2024

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

June 06, 2024

Via Benzinga

Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 06, 2024

Via Benzinga

Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings ↗

June 06, 2024

Via Benzinga

Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? ↗

June 06, 2024

Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was...

Via Benzinga

J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday ↗

June 06, 2024

Via Benzinga

REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024 ↗

May 16, 2024

REPL stock results show that Replimune Group missed analyst estimates for earnings per share the fourth quarter of 2024.

Via InvestorPlace

Crude Oil Moves Lower; AutoZone Profit Tops Views ↗

December 05, 2023

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&P 500...

Via Benzinga

Topics Stocks

Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

December 05, 2023

Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

December 05, 2023

Via Benzinga

Dow Falls 100 Points; ISM Services PMI Increases In November ↗

December 05, 2023

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday. The Dow traded down 0.28% to 36,103.52 while the NASDAQ rose 0.32% to 14,230.64. The S&P...

Via Benzinga

Topics Stocks

Why Is Replimune (REPL) Stock Down 48% Today? ↗

December 05, 2023

Replimune stock is dropping on Tuesday as investors in REPL shares react to a clinical trial missing both of its primary endpoints.

Via InvestorPlace

US Stocks Down; JM Smucker Posts Upbeat Earnings ↗

December 05, 2023

U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.23% to 36,120.88 while the NASDAQ fell...

Via Benzinga

Topics Stocks

What's Going On With Cancer-Focused Replimune Stock Today? ↗

December 05, 2023

Replimune Group Inc (NASDAQ: REPL) announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for locally advanced or metastatic cutaneous

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 05, 2023

Via Benzinga

8 Health Care Stocks Whale Activity In Today's Session ↗

November 07, 2023

Via Benzinga

Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma

July 31, 2023

From Incyte

Via Business Wire

Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review ↗

June 09, 2023

The Nasdaq held near 52-week highs while small caps ramped up.

Via Investor's Business Daily

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.